Ever thought of the difference between an ACL tear and an MCL tear Learn what makes the two different despite being located ...

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's (NASDAQ:AZN) Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with ...

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...